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Summary 
The goal of the current study was to examine the formation of phospholipids,  1-radyl-2-1yso- 
sn-glycero-phospholipids  (lyso-PL)  and 2-acetylated phospholipids  (such  as  PAF)  as well as 
mechanisms  responsible  for  generating these  phosphohpids  in  bronchoalveolar lavage fluid 
(BALF) from allergic subjects  challenged with antigen. Bronchoalveolar lavage was performed 
in normal and allergic  subjects  before, 5-30 min, 6 h, and 20 h  after segmental antigen chal- 
lenge via a wedged bronchoscope.  Levels of 1-hexadecyl-2-1yso-phospholipids and 1-hexade- 
cyl-2-acetyl-phospholipids were initially determined by negative ion chemical  ionization gas 
chromatography/mass spectrometry (NICI-GC/MS). Antigen dramatically elevated quantities 
of l-hexadecyl-2-1yso-phospholipids in allergic subjects 20 h after challenge when compared to 
non-allergic controls. In contrast, there was not a significant increase in levels of 1-hexadecyl- 
2-acetyl-phospholipids after antigen challenge. Closer examination of 1-radyl-2-1yso-sn-glyc- 
ero-3-phosphocholine (GPC) revealed that 1-palmitoyl-2-1yso-GPC,  1-myristoyl-2-1yso-GPC and 
1-hexadecyl-2-1yso-GPC were three major molecular species produced after antigen challenge. 
1-palmitoyl-2-1yso-GPC increased sevenfold to levels of 222  +  75 ng/ml of BALF 20 h after 
antigen challenge. The elevated levels of lyso-PL correlated with levels of albumin used to as- 
sess plasma  exudation induced by allergen challenge. In contrast, the time course of prosta- 
glandin D2 (PGD2) or 9or, 1 I[3PGF2 (1 I~PGF2) formation did not correlate with lyso-PL gen- 
eration. 
To examine the mechanism leading to lyso-phospholipid formation in antigen-challenged 
allergic  subjects,  secretory phospholipase A  2 (PLA2) and ace@ hydrolase activities  were mea- 
sured. There was a significant increase in PLA2 activity found in BALF of allergic subjects chal- 
lenged with antigen when compared to saline controls. This activity was neutralized by an an- 
tibody directed against low molecular mass, (14 kD) human synovial PLA2 and dithiothreitol. 
Acetyl hydrolase activity also markedly increased in BALF obtained after antigen challenge. 
This study indicates that high levels oflyso-PLs are present in airways of allergic subjects  chal- 
lenged with antigen and provides evidence for two distinct mechanisms that could induce lyso- 
PL formation. Future studies will be necessary to determine the ramifications of these high lev- 
els oflyso-phospholipids on airway function. 
A 
sthma is a complex disease characterized by increased 
airway  responsiveness  to  diverse  stimuli  and  mani- 
fested by airway narrowing and inflammation (for review 
see reference 1). Evidence indicates that airway inflamma- 
tion in asthma is characterized by an influx of inflammatory 
cells into airways and the release  of inflammatory media- 
tors, including biologically active phospholipids. One fam- 
ily  of 2-acetylated phospholipids,  collectively known  as 
platelet-activating factor (PAF) 1,  is released by inflamma- 
tory cells in vitro in response antigenic and nonantigenic 
~Abbreviations used in this paper: BAL,  bronchoalveolar  lavage; BALF,  BAL 
fluid; DTT, dithiothreitol;  FEV~, forced expiratory  volume  in 1 s; GPC, 
1-radyl-2-1yso-sn-glycero-3-phosphocholine;  HG, hydrofluoric  acid; lyso- 
PC, lyso-phosphatidylcholine;  PAF, platelet-activating  factor; PFB, pen- 
tafluorobenzoyl;  PLA  2, phospholipase A2; PNU, protein nitrogen units; 
TLC, thin layer  chromatography. 
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in vitro suggest that the release of PAF in vivo into the hu- 
man airway may modulate  certain characteristics  of asthma 
such  as  bronchoconstriction,  cellular  infiltration,  mucous 
hypersecretion,  microvascular  leakage,  and  bronchial  hy- 
perreactivity (4-16). 
Lyso-phosphohpids  are  another  family of phospholipids 
which  have  been  proposed  to  regulate  tissue  injury.  Al- 
though  this phospholipid family has received a little atten- 
tion  in lung injury,  it has been  recognized  for some time 
that the heart generates large quantities oflyso-phospholipids 
during  injury  such  as  myocardial ischemia  (17-20).  Once 
formed,  these  lyso-phosphohpids  have been  hypothesized 
to  contribute  to  electrophysiologic  alterations  that lead to 
arrhythmogenesis  (18,  19,  21-28).  A  few investigations  in 
animal models have also suggested  that lyso-phospholipids 
can participate in lung injury by increasing lung resistance, 
inducing capillary permeability and altering surfactant prop- 
erties  (29-31).  However,  the formation of large quantities 
of lyso-phospholipids  in  response  to  injury  has  not  been 
clearly demonstrated in the human lung. 
Lyso-phosphohpids can be generated in tissues by several 
different mechanisms. The most direct mode of synthesis is 
the hydrolysis of long chain fatty acids from the sn-2 posi- 
tion of membrane glycerolipids of tissues (32, 33). A family 
of phospholipase  A 2 enzymes  of relatively  low  molecular 
mass  (~14  kD  in  size)  classified  as  group  I,  group  II and 
group III phospholipase A 2 (PLA2) has been isolated as ex- 
tracellular  enzymes  (for review see reference 34).  In addi- 
tion to their small sizes, they have high disulfide bond con- 
tent  and  require  millimolar  calcium  for  catalysis.  One 
member of this family, group II PLA2, has been imphcated 
in the pathogenesis of many inflammatory diseases (35-38). 
This  enzyme  has been  shown  to  be  released from several 
cells  including  mast  cells  during  immunologic  challenge 
(39,  40).  Group II PLA  2 is present in high quantities in in- 
flammatory sites such as peritoneal exudates from caseinate- 
treated animals, synovial fluids from patients with rheuma- 
toid  arthritis,  and  nasal  lavage  fluids  from  atopic  subjects 
challenged  with  antigen  (41-44).  In  addition,  circulating 
levels of secretory PLA  2 increase in several illnesses includ- 
ing sepsis, shock, severe injury, and pancreatitis  (45, 46). 
A  more  indirect  pathway  that  can  generate  lyso-phos- 
pholipids  is the hydrolysis of the  acetyl moiety at the sn-2 
position  of 2-acetylated  phospholipids  that  are  generated 
during tissue injury. Both serum and cellular acetyl hydro- 
lase have been described as enzymes that are clearly distinct 
from  PLA  2 isotypes  (47-49).  Recent  studies  by  Tjoelker 
and  colleagues suggest that the  quantities  of acetyl hydro- 
lase that are found  in tissues dramatically influence  the  re- 
sponse of that tissue to PAF  (50). 
In the  current  study, we examine the in vivo formation 
of phosphohpid  products,  lyso-phospholipids,  and  PAF, 
from the PLA  2 and/or acetyl hydrolase reactions in airways 
of allergic  individuals  challenged  with  antigen.  This  study 
indicates  that  high  levels  of lyso-phospholipids  as  well  as 
secretory PLA  2 and acetyl hydrolase are present in antigen- 
stimulated  airways.  Furthermore,  they  raise  fundamental 
questions as to the role oflyso-phosphohpids in lung injury. 
Materials and Methods 
Study Population.  Before the evaluation of subjects,  protocols 
received Institutional Review Board approval, and informed con- 
sent was obtained. Four normal non-allergic, non-asthmatic sub- 
jects and three allergic asthmatic  subjects underwent bronchoscopy 
and baseline bronchoalveolar lavage (BAL) without antigen chal- 
lenge.  26 allergic subjects (9 with rhinitis alone and 17 with asthma 
and rhinitis)  underwent segmental antigen challenge via a wedged 
bronchoscope and were lavaged at various time intervals (from 
5 rain to 20 h) following challenge. Bronchoalveolar lavage fluid 
(BALF)  were  assayed  for  2-acetylated  phospholipids  and  lyso- 
phospholipids.  Subjects were men and women between 20 and 
33 yr of age with no history of smoking. Subjects were classified 
as allergic asthmatics on the basis of clinical criteria,  methacholine 
reactivity,  and  immediate-type  skin  testing  as  previously  de- 
scribed (51). All asthmatic subjects  reported a history of episodic 
wheezing,  shortness  of breath  or  chest  tightness,  and  demon- 
strated a positive methacholine  challenge  test,  defined as a 20% 
fall in the forced expiratory volume in 1 s (FEV1) to a methacho- 
line  concentration  <25  mg/ml. Allergic  rhinitic  subjects  had  a 
history of asthmatic symptoms and no response to methacholine 
at concentrations of 25 mg/ml. Atopic status was determined by 
prick-puncture skirl testing with a battery of nine common inhal- 
ant allergens.  All allergic  subjects  had two or more positive skin 
test reactions and were responsive to ragweed, Timothy grass, or 
dust mite used for segmental allergen challenge. All normal sub- 
jects had no history of asthma, were unresponsive to methacho- 
line,  and had no  positive skin  test reactions.  All  subjects  had  a 
FEV~  >80%  predicted,  were  asymptomatic,  and  required  no 
medications for control of symptoms at the time of the study. No 
subject had a history of viral respiratory tract infection during the 
month before the study. 
Bronchoalveolar Lavage and Segmental Antigen Challenge.  Bron- 
choalveolar lavage was performed using a standardized protocol 
in accordance with guidelines established  by a National Institutes 
of Health Workshop as previously described (52).  Subjects were 
premedicated with atropine (0.6 mg IM). After inhalation of neb- 
ulized  lidocaine  (4%),  an  Olympus BF-10  fiberoptic  broncho- 
scope was inserted into the airway. Local anesthesia  was supple- 
mented with lidocaine  (2%) instilled  via the bronchoscope. The 
bronchoscope  was  wedged  in  a  subsegmental  bronchus  and  a 
control sham challenge with 5 nil normal saline was performed. 
Antigen challenge was then performed by instilling  5 ml of anti- 
gen in a subsegment of the contralateral lung. Instillation of saline 
was always performed first to avoid contamination of the control 
subsegment  by  residual  antigen  via  the  bronchoscope.  In  this 
manner, each subject provided responses to saline control and to 
antigen.  Most subjects  were challenged with a total dose of 500 
protein  nitrogen  units  (PNU)  of antigen,  either short  ragweed 
(Ambrosia elatior, Greer Laboratories, Inc., Lenoir, NC), dust mite 
(Dermatophagoides farinae; Hollister-Stier, Miles  Inc., Elkart,  IN), 
or Timothy grass (Phleum  pratense; Hollister-Stier,  Miles). 1 PNU/ml 
contained  0.005  ~g/ml  of ragweed  antigen  E.  The  endotoxin 
concentration of a  100 PNU/ml ragweed dilution was 0.05  en- 
dotoxin units measured using a colorimetric Limulus lysate assay. 
Bronchoalveolar lavage was performed by instilling  5 ￿  20-ml al- 
iquots of normal saline, preheated to 37~  with immediate aspi- 
ration of each aliquot.  Fluids  returned form each segment were 
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ranged from 45-60%.  Upon  recovery, BALF were pooled and 
filtered through gauze. Aliquots were immediately acidified with 
8.8% formic acid (20 I~l/ml) to inactivate acid-labile acetylhydro- 
lase. Fluids were then centrifuged (10 rain, 400g) to remove cells. 
10  ng  of  the  1-0-16,16,16-trideuterohexadecyl-2-acetyl-GPC 
analogue  of PAF  (Biomol,  Plymouth  Meeting,  PA),  and  two 
nanograms  of 1-0-7,7,8,8-tetradeuterohexadecyl-2-1yso-l-radyl- 
2-1yso-sn-glycero-3-phosphocholine  (GPC), a tetradeuterated ana- 
logue oflyso-PAF (Cayman Chemical, Ann Arbor, MI), were added 
to 2-ml aliquots of the cell-free supernatant fluids before sample 
extraction  and  derivatization procedures.  BALF  with  internal 
standards  were  extracted and  derivatized immediately or were 
stored at -70~  for subsequent extraction and derivatization. 
Quantification  of 2-acetylated Phospholipids and Lyso-phospholipids 
in BALF.  BALF  samples  were  extracted,  and  the  pentafluo- 
robenzoyl ester derivatives of 2-acetylated and lyso-phospholipids 
were synthesized and quantitated by combined capillary gas chro- 
matography-mass spectrometry using modifications of methods 
previously described (53, 54). Briefly, 2-ml aliquots of BALF ob- 
tained and treated as described above were extracted with octade- 
cylsilane cartridges (C18,  Sep-Pak)  (Waters Associates, Milford, 
MA)  (55).  Cartridges were  conditioned with  10  ml  of HPLC 
grade methanol (Fisher Chemical Co., Fairlawn, NJ) followed by 
10 ml of HPLC grade water (Baker Chemical Co., Phillipsburg, 
NJ). 4 ml of methanol (Fisher Chemical Co.) and 4 ml of HPLC 
grade water (Fisher Chemical Co.) were added to 2-ml aliquots 
of acidified BALF containing the deuterated internal standards, 
creating  a  40%  (vol/vol)  methanol/water  mixture.  The  40% 
methanol/water mixture was then loaded directly onto the con- 
ditioned cartridges, and the cartridge washed with 5 ml of water. 
The effluents from the loading and washing procedures were dis- 
carded. Phospholipid fractions containing 2-acetylated- and lyso- 
phospholipids were eluted from the cartridges with 5 ml of meth- 
anol and collected in Teflon-coated Oak-Ridge centrifuge tubes 
(Nalgene Co., Rochester, NY). The eluting solvent and residual 
water were evaporated under a nitrogen stream leaving a residue 
containing the eluted phospholipids. To remove the phosphobase 
moiety of extracted phospholipids, the residue was treated with 
500  Ixl of 49% hydrofluoric acid (HF) (Fisher Chemical Co.) and 
1 rul hexane (Fisher Chemical Co.) with continuous shaking for 
4 h  at room temperature. The upper hexane layer was then re- 
moved, transferred to a clean silanized glass vial and dried under a 
stream of nitrogen. The pentafluorobenzoyl (PFB)  esters  of the 
resulting diglycerides were  then  synthesized by the  addition of 
PFB esterification reagent. The pentafluorobenzoyl esterification 
reagent was prepared as follows: methylene chloride (Fisher Chemi- 
cal Co.) was dried by passage  of the solvent over anhydrous so- 
dium sulfate (Aldrich Chemical Co., Milwaukee, WI). 2 mg of 
dimethylaminopyridine (Aldrich Chemical Co.) was then added 
to 600 Ixl of anhydrous methylene chloride, followed by the addi- 
tion of 4 txl ofpentaflurobenzoyl chloride (Aldrich Chemical Co.). 
50 I~1 of the resultant PFB esterification reagent was then placed 
onto the dried hexane residue and heated at 60~  for 5 rain. The 
reaction solvent was evaporated under nitrogen, and the solid res- 
idue extracted twice with 0.5 ml of hexane and transferred to a 
clean silanized glass vial. The hexane-extracted product was then 
evaporated under nitrogen and dissolved in 30  Ixl of dodecane 
(Aldrich Chemical Co.) for injection into the capillary gas chro- 
matograph. The  recovery of analytes during solid-phase extrac- 
tion and derivatization procedures was determined by the addi- 
tion ofradiolabeled [3H]PAF and [3H]lyso-PAF (100,000 cpm) to 
each BALF. Recovery of HF hydrolysis products of [3H]PAF and 
[3H]lyso-PAF was 95%. The overall yield throughout the extrac- 
tion and esterification procedures was >60% (data not shown). 
GC/MS  analysis  of derivatized phospholipids extracted from 
BALF was performed with a Varian 3400  GC interfaced with a 
Finnigan MAT TSQ-700  GC/MS/MS/DS  operated as a single 
stage  quadrapole.  The  mass  spectrometer was  operated in  the 
negative  ion  chemical  ionization  mode  using  methane  (Ultra 
High Purity; Matheson Gas Products, Bridgeport, NJ) at a pres- 
sure of 0.8-1.0  tort as the reagent gas. An emission current of 
200 mA with an electron energy of 70V was employed for ion- 
ization.  Characteristic molecular anions at m/z  552  (PAF) and 
555  (2H3-PAF) were monitored for measurement of in vivo PAF 
levels.  1-hexadecyl-2-1yso-phospholipid levels were  determined 
by  monitoring  of the  characteristic  molecular  anion  for  the 
bispentafluorobenzoyl ester (PFBOE)2 of the monoglyceride (ob- 
tained after HF treatment) at m/z 704 using 2H4-1yso-PAF [signal 
at m/z 708] as an internal standard. 
In  a  separate  series  of studies,  levels  of 1-myristoyl-2-1yso- 
GPC,  1-hexadecyl-2-1yso-GPC and  1-palmitoyl-2-1yso-GPC in 
BALF from seven atopic subjects obtained 20 h after antigen and 
saline  challenges  were  determined.  2H4-1-Hexadecyl-2-1yso- 
GPC  (5  ng)  served as the  internal standard for the  three lyso- 
phosphatidylcholines (lyso-PC) and was added to BALF before 
solid-phase extraction.  A  lyso-phosphatidylcholine fraction was 
obtained via thin-layer chromatography before HF hydrolysis of 
the polar head group. Briefly, the  methanol  eluate from solid- 
phase extraction was dried, dissolved in 100  txl of methanol and 
spotted onto silica gel G  TLC plates and developed in a chloro- 
form/methanol/acetic  acid/water  (50:28:8:3,  vol/vol/vol/vol) 
solvent system. The resolved lyso-PC fraction of the TLC plate 
was scraped and extracted (3 ￿  with 5-ml vol of methanol/water 
(3:1,  vol/vol). The  dried extract was then treated with HF for 
hydrolysis  of the  polar  head  group  as  described  above.  The 
monoglycerides generated via HF treatment of the lyso-phospho- 
lipids were extracted with hexane and transferred to a clean si- 
lanized glass vial. After solvent removal under a nitrogen stream, 
the monoglycerides were treated with pentafluorooenzoyl chlo- 
ride in the presence of 4-dimethylaminopyridine and prepared for 
analysis  as  described  above.  The  (PFBOE)2  derivative  of the 
monoglycerides were detected by monitoring molecular anions at 
m/z  690,  m/z  704,  m/z  718,  and  m/z  708,  for  elution  of 
1-myristoyl-(PFBOE)2,  l-0-hexadecyl-(PFBOE)2,  1-palrnitoyl- 
(PFBOE)2 and 2H  4 1-0-hexadecyl-(PFBOE)2, respectively. Un- 
fortunately, we were unable to measure concentrations of 1-stearoyl- 
2-1yso-GPC in BALF by GC/MS because of a major contamination 
peak found in BALF that mi~gated with the 1-stearoyl-(PFBOE)2. 
Prostaglandin D 2 and Albumin Measurements in BALF.  PGD  2  and 
its metabohte, 9or,  1113-PGF2(1 I[3-PGF2), were assayed in BALF 
samples to determine if release of these inflammatory lipid media- 
tors had been initiated following antigen challenge. Both prosta- 
glandins were assayed by combined GC/MS using previously pub- 
lished methods  (56).  Limits of detection  of the  prostaglandins 
were 0.1-0.2 pg/ml BALF. Albumin was also  assayed in lavage 
fluids and served as an index of airway permeability after segmen- 
tal antigen challenge. Albumin was quantified using a sensitive ra- 
dioimmunoassay (51). 
Phospholipase A2 Activity in BALF.  BALF  for  PLA2  activity 
measurements was obtained from five ragweed allergic, asthmatic 
subjects. These subjects were challenged with ragweed antigen at 
concentrations ranging between 20 and 500 PNU and were lav- 
aged 20 h after challenge. Phospholipase A2 activity in BALF was 
2237  Chilton et al. measured  as  described by  Fonteh  and  colleagues  (40).  Briefly,  400. 
PLA  2 activity was determined in 50 mM Tris HCL (pH 7.4)  and 
10 mM CaC12 in a total volume of 1.0 ml. This reaction was ini- 
tiated by  the  addition of 0.1  ~Ci  (9.7  nmol)  [3H]AA-labeled  "~ 
Escherichia coti membranes (New England Nuclear, Boston, MA).  ~'~  300. 
After incubation (90 min at 37~  in a water bath, the reaction 
was stopped by extracting lipids by the method of Bligh and Dyer 
(40).  Free fatty acids were isolated from phospholipids by TLC  ~, 
on  silica gel  G  developed in  hexane/ethyl  ether/formic  acid 
(90:60:6, vol/vol). The radioactivity in lipids was located by us-  ~  ~" 
t",l  ing a radiochromatogram imaging system (Bioscan Inc., Wash- 
ington, DC).  Free AA and phospholipids were isolated by TLC 
zonal scrapping and the quantity of radioactivity determined by  ~  10O. 
liquid scintillation counting. PLA2 activity was calculated and ex- 
pressed as pmol AA released/h/m] of BALF.  .~, 
In some experiments, the effects of antibody (F10-mAb) neu- 
tralization and dithiothreitol (DTT) on PLA2 activity were exam- 
ined. Portions of  BALF were incubated (1 h, 37~  with different 
concentrations of neutralizing antibody (F10-mAb) raised against 
recombinant  human  synovial fluid PLA  2.  The  antibody was  a 
generous gift of Dr. Lisa Marshall (SmithKline Beecham, King of 
Prussia,  PA).  PLA  2 activity was  determined in supematant fluid 
fractions as described above. In other experiments, the effect of 
DTT on BALF PLA  2 activity was examined. Briefly, BALF was 
incubated with DTT on ice for 15 min. Subsequently, PLA  2 ac- 
tivity was measured as described above. 
Acetyl Hydrolase Activity in BALF.  The metabolism of PAF in 
BALF obtained from four allergic asthmatic subjects before and 
after antigen challenge was determined to ascertain acetyl hydro- 
lase levels. [3H]PAF (1 l,~Ci, 5 pmol; New England Nuclear, Bos- 
ton,  MA) was added (complexed to  albumin  [0.25  mg/ml])  to 
5-ml aliquots of BALF obtained before, 5-30 min and 20 h after 
segmental antigen challenge via a wedged bronchoscope. BALF 
were  maintained at  37~  and  1-ml  aliquots  of fluid were  re- 
moved at 0,  I0, 30, 60, and 90 min. Reactions were terminated 
by Bligh-Dyer extraction. The  extracted phospholipid fractions 
were subjected to thin layer chromatography (TLC)  using silica 
gel G plates with chloroform~methanol~acetic  acid/water (50:28: 
8:3, vol:vol) as the developing system. The rate of metabolism of 
PAF to its [3H]lyso-PAF was determined by assessing the distribu-  30. 
tion of the radiolabel into the  [3H]PAF and [3H]lyso-PAF frac- 
tions by liquid scintillation spectrometry. 
Statistical Analysis.  Statistical  analysis  between  groups  was 
made using Student's paired t-test. Correlations were assessed us- 
ing Spearman rank correlation analysis. 
Results 
Formation of 2-acetylated  Phospholipids  and Lyso-phospholip- 
ids in Human Airways.  Initial  experiments  were  designed 
to examine the quantities of PAF and closely related 2-acety- 
lated  analogs  (i.e.,  1-hexadecyl-2-acetyl-phospholipids) as 
well as lyso-phospholipids containing an 1-hexadecylqink- 
age at the sn-1  position of the glycerol backbone in BALF 
fluids. Levels of 1-hexadecyl-2-acetyl-phospholipids as de- 
termined by GC/MS  are depicted in Fig.  1.  Quantities of 
2-acetylated phospholipids in allergic subjects were near or 
below the  detection limits (50  pg/ml)  of the  assay before 
antigen challenge. These values were not significantly dif- 
ferent from  those found in non-allergic subjects (data not 
shown).  Antigen  challenge  did  not  significantly increase 
20  hr 
5-30 main  6 hr 
O.  m~ 
n--$  n--3  n=12 
Figure  1.  1-Hexadecyl-2-acetyl-phospholipid levels before and  after 
antigen challenge. BALFs  were obtained at the indicated times after anti- 
gen  challenge. Internal  standards were  added  and  lipids  extracted. 
2-Acetylated phospholipids were converted to pentafluorobenzoyl deriv- 
atives and  analyzed by NICI-GC/MS.  1-hexadecyl-2-acetyl-phospho- 
lipid levels in the absence and presence of antigen are shown. These data 
are the means + SEM.., Normal saline; [], antigen. 
quantities of 2-acetylated phospholipids in BALF of allergic 
subjects 5-30 rain, 6 or 20 h after challenge. We next mea- 
sured the quantities of 1-hexadecyl-2-1yso-phospholipids in 
BALF of allergic subjects before challenge and found 22  +-- 
0.9  ng/ml,  a  value  20-30-fold  higher  than  2-acetylated 
phospholipids. These levels were not significantly different 
from those found in nonallergic subjects (data not shown). 
~  20. 
~  10. 
20 hr 
$-30 rain  6 hr 
n--$  n=3  n=12 
1-Hexadecyl-2-lyso-phospholipid levels before and after an-  Figure 2. 
tigen challenge. BALFs were obtained at the indicated times after antigen 
challenge. Internal standards  were added and lipids extracted. Lyso-phos- 
pholipids were converted to bispentafluorobenzoyl derivatives and ana- 
lyzed by NICI-GC/MS. 1-hexadecyl-2-1yso-phospholipid  levels in the 
absence and presence of antigen are shown. These data are the means -+ 
SEM. I, Normal saline; [~, antigen. *P <0.05. 
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crease in quantities of 1-hexadecyl-2-1yso-phospholipids in 
BALF of allergic subjects at 5-30 rain and 6 h after antigen 
challenge when  compared  to  saline  challenge.  However, 
levels of 1-hexadecyl-2-1yso-phospholipid were significantly 
increased (compared to saline  challenge or baseline levels) 
20 h after antigen challenge (P <0.05). 
While these initial studies measured one select subclass of 
lyso-phospholipid,  1-hexadecyl-2-1yso-phospholipid,  they 
provided no data regarding other lyso-phospholipid molec- 
ular species that may be produced during antigen challenge. 
To address this question, 1-radyl-2-1yso-GPC molecular spe- 
cies were isolated by TLC and analyzed by NICI-GC/MS. 
Fig.  3  illustrates  the  GC/MS  analysis  of several  lyso-PC 
molecular species found in the BALF of seven allergic sub- 
jects 20  h  after antigen challenge.  Levels of 1-palmitoyl- 
2-1yso-GPC,  1-myristoyl-2-1yso-GPC  and  1-hexadecyl- 
2-1yso-GPC  were  increased  five-  to  ninefold  in  allergic 
subjects  challenged for 20 h with antigen when compared 
to saline challenge controls. In particular, levels of 1-palmi- 
toyl-2-1yso-GPC were high (222  ng/ml +  75)  in the late 
phase  BALF.  Fig.  4  illustrates  the  individual  levels  of 
1-palmitoyl-2-1yso-GPC in seven subjects.  While 1-palmi- 
toyl-2-1yso-GPC levels increased in the BALF of all subjects 
a~er antigen challenge, the degree of change varied a great 
deal between individual subjects.  The level of 1-palmitoyl- 
2-1yso-GPC in the BALF of one subject were extremely 
high approaching 700 ng/ml. 
Phospholipase A 2 Actim'ty in Human Airways.  To gain some 
understanding into the mechanism(s) leading to the marked 
increases in 1-radyl-2-1yso-GPC molecular species in BALF, 
the activities of two potential enzymes that could regulate 
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phatidylcholme molecular species. BALFs were obtained 20 h after antigen 
challenge. Lipids were extracted and lyso~phosphatidylcholine isolated by 
TLC.  Lyso-phosphatidylcholine molecular species were then converted 
to  bispenta~fluorobenzoyl derivatives and  analyzed by  NICI-GC/MS. 
These data are the means +- SEM of seven separate patients. I1, Normal 
saline;  ['-], antigen. *P <0.05. 
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Figure  4.  Influence  of antigen  challenge  on  levels  of 1-palmitoyl- 
2-1yso-GPC in seven allergic  subjects. BALFs were obtained 20 h  after 
antigen challenge. Lipids were extracted and lyso-phosphatidylcholine iso- 
lated by TLC. Lyso-phospholipids were then converted to bispentafluo- 
robenzoyl derivatives and analyzed by NICI-GC/MS. These are the indi- 
vidual  measurement~  of  1-palmitoyl-2-1yso-GPC  from  seven  separate 
patients. 
lyso-phospholipids levels were measured. PLA2 activity was 
assayed by measuring the capacity of cell-free BALF to hy- 
drolyze  [3H]AA  from labeled  E.  coli membranes.  Fig.  5 
shows the PLA2 activity in BALF from five allergic subjects 
challenged for 20 h with saline or antigen. BALF from sa- 
line  challenged  sites  contained  relatively  high  levels  of 
PLA2 activity (981 +--  121  pmol/h/ml BALF). In addition, 
there was a modest and significant increase in PLA  2 activity 
found in BALF after antigen challenge when compared to 
saline challenge. PLA2 activity increased after antigen chal- 
lenge in the BALF of all five subjects tested. 
To better characterize this PLA2 activity, BALF from al- 
lergic subjects  (saline and antigen challenged) were exposed 
to either a neutralizing antibody (F10) directed against low 
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Figure  5.  PLA  2 activity before and after antigen challenge. BALFs were 
obtained 20 h after antigen challenge. PLA  2 activity was determined using 
labeled E. coli membranes as described in the methods. These are the mea- 
surements from five patients challenged with saline and antigen. *P <0.05. 
2239  Chilton et al. molecular secretory PLA2,  or a reducing agent, dithiothrei- 
tol  (Fig.  6, A  and B).  Both  the  neutralizing antibody and 
dithiothreitol blocked the  activity of PLA  2 in BALF in a 
dose-dependent manner. These data reveal that the BALF 
of allergic subjects contain high levels ofPLA  2 activity with 
characteristics of low molecular weight, group II PLA  2. 
Acetyl Hydrolase Activity in Human Airways.  An increase in 
lyso-phospholipid levels could also result from the hydroly- 
sis of an acetyl moiety from the sn-2 position of the glyc- 
erol backbone. Both cellular and serum acetyl hydrolase ac- 
tivities which  are  distinct from  classical  PLA  2 have  been 
described (47-50). Acetyl hydrolase activity was determined 
in BALF by monitoring the catabolism of [3H]PAF. [3H]PAF 
was added to BALF recovered before and 5-30 rain and 20 h 
after antigen challenge. Fig.  7  indicates that acetyl hydro- 
lase  activity  in  BALF  varies  significantly depending  on 
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Figure  6.  Effect  ofF-10 antibody  and dithiothreitol  on BALF PLA2 ac- 
tivity. BALFs were obtained 20 h after antigen challenge. The fluids were 
treated with an antibody (F10) that neutralizes  human synovial  PLA  2 and 
DTT. PLA2 activity was determined using labeled E. coli membranes  as 
described in the methods. These are the measurements  from three patients 
challenged with antigen. *P <0.05. 
whether  the  antigenic response  has  been  initiated.  Top, 
middle, and bottom panels illustrate acetyl hydrolase activ- 
ity  before,  5-30  rain  and  20  h  after  antigen  challenge. 
Whereas acetyl hydrolase activity is present before antigen 
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Figure 7.  Acetyl  hydrolase activity in BALF before and after antigen 
challenge. BALFs were obtained at the indicated  times after antigen chal- 
lenge. Labeled PAF was incubated  in BALF and metabolites  were isolated 
by TLC. These data show the conversion of PAF to lyso-PAF and are 
means -+  SEM of four patients at each time point. ~,  PAF; -K3--, 
lyso-PAF. 
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Figure 9.  Correlation between 1-hexadecyl-2-1yso-phospholipids  and 
albumin levels. BALFs  were obtained 20 h after antigen challenge. Inter- 
nal standards were added to an aliquot of the BALF and lipids extracted. 
Lyso-phospholipids were converted to bispentafluorobenzoyl derivatives 
and analyzed by NICI-GC/MS. Albumin levels were determined in an- 
other aliquot as described in the methods. P = 0.004 by Spearman Rank 
correlation. 
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Figure  8.  PGD  2 and  1113PGF  2 levels before and after antigen chal- 
lenge. BALFs  were obtained at the indicated times after antigen challenge. 
Internal standards were added and lipids were extracted. Prostaglandins 
were derivatized as described and analyzed by NICI-GC/MS. PGD2 and 
1  I[3PGF  2 levels in the absence and presence of antigen are shown. These 
data are means -  SEM. I, Normal saline; [], antigen. *P <0.05. 
challenge,  there  is  a  time-dependent  increase  in  BALF 
acetyl hydrolase activity after antigen challenge. At 20 h af- 
ter antigen  challenge,  >80%  of added  PAF is  hydrolyzed 
within 30 rain. 
Correlation of Lysophospholipid Levels with Changes in Pros- 
taglandin D 2 and Albumin in Human Airways.  The next se- 
ries  of experiments  were  designed  to  examine  whether 
changes in lysophospholipid levels could be correlated with 
other markers of antigen activation. Levels of PGD  2 and its 
metabolite  1113-PGF  2 were measured by NICI-GC/MS in 
BALF obtained before, 5-30 rain,  6 and 20 h  after antigen 
challenge.  Levels  of both  PGD  2 and  1 I[3-PGF  2 increased 
significantly 5-30 rain  (Fig.  8)  after challenge when  com- 
pared  to  saline  challenge  levels.  PGD  2 levels  were  much 
lower but remained  shghfly elevated  over saline  challenge 
levels at 6 and 20 h. These data demonstrated that the time 
course of formation ofPGD 2 and 1 I[3PGF2 was clearly dif- 
ferent than that seen for lyso-phospholipids.  In contrast to 
these  prostaglandins,  albumin  levels  were  markedly  ele- 
vated 20 h after antigen challenge (Fig. 9). When these lev- 
els  were  compared  to  levels  of 1-hexadecyl-2-1yso-phos- 
pholipids  in  individual  subjects,  there  was  a  significant 
correlation between albumin and  1-hexadecyl-2-1yso-phos- 
pholipid levels. 
Discussion 
Studies in a variety of tissues and the heart, in particular, 
have shown that high concentrations oflyso-phosphohpids 
are  generated  during injury.  This  can be  demonstrated  in 
vitro with isolated myocytes, in models of ischemia-peffu- 
sion injury, or in vivo during myocardial infarction. Whereas 
the exact role of these lyso-phospholipids in heart injury is 
not dear, it is known that they can contribute to membrane 
dysfunction, electrophysiological alterations, lethal arrhyth- 
rajas,  and  cellular  injury  of the  ischemic  myocardium.  In 
contrast to the heart,  there have been few studies  examin- 
ing the role oflyso-phosphohpids in lung injury.  This may 
be due,  in large part,  to the fact that it is difficult to mea- 
sure lyso-phospholipids in tissues and that there have been 
few studies that have reported lyso-phospholipid formation 
at  significant  levels  in  the  lung.  It  has  been  shown  that 
measurable  quantities  of lyso-PAF are present in BALF of 
both normal,  rhinitic  and asthmatic subjects  (12,  57).  iLe- 
suits in the current study reveal that relatively high concen- 
tration  of lyso-phospholipids reside  in the  epithelial  lining 
fluid of allergic  subjects and levels  dramatically increase during 
2241  Chilton et al. challenge with antigen. Whereas all potential molecular spe- 
cies of lyso-phospholipids were not examined, these  data 
indicate that at least three major molecular species, 1-myris- 
toyl-2-1yso-GPC,  1-hexadecyl-2-1yso-GPC  and  1-palmi- 
toyl-2-1yso-GPC are found in BALF of human airways. 
At least two fundamental questions arise from these data: 
(a) what are the roles of these high concentrations of lyso- 
phospholipids in lung injury? and (b)  what are  the  enzy- 
matic mechanism(s) which generate lyso-phospholipids in 
human airways?  In regard to the former, the role of lyso- 
phospholipids  in  lung  injury has  not been  clearly eluci- 
dated.  However, mean BALF concentrations of 1-palmi- 
toyl-2-1yso-GPC at 20 h were 222 ng/ml and reached levels 
of 685 ng/ml in one subject. Since the amount of saline in- 
jected into  the bronchus  could dilute  the  alveolar lining 
fluid from 50- to 100-fold (58), the mean concentration of 
1-palmitoyl-2-1yso-GPC in lining fluid may range from 25 
to 50 ~xM after antigen challenge and could reach 150 ~M 
in some subjects.  Lyso-phospholipids levels this high affect 
several biological processes  that could alter lung function. 
These concentrations are  10-20-fold higher than the criti- 
cal micelle (aggregate)  concentration for lyso-PC, and this 
physical form of lyso-phospholipids  can disrupt cellular mem- 
branes via detergent effects resulting in cytolysis. For exam- 
ple, PLA  2- induced lyso-PC formation in isolated hamster 
lungs has been correlated with type I epithelial cell toxicity 
(29, 33). In addition to detergent effects, lyso-PC can irre- 
versibly inactivate surfactant (30) by its capacity to disorder 
the surface film thereby reducing the ability to lower sur- 
face tension. Lyso-phospholipids have also been shown to 
increase  airway and capillary  permeability in isolated per- 
fused rat lungs (31). The fact that albumin concentrations 
increase  as a  function of the  concentration of lyso-phos- 
pholipids in BALF further emphasizes the potential role of 
lyso-phospholipid in  inducing cell  injury and changes in 
airway  permeability.  There  is  also  some  question  as  to 
whether  the  lyso-phospholipids could serve  as precursors 
for the  biosynthesis  of 2-acetylated phospholipids  such  as 
PAF.  For  example,  we  have  demonstrated that activated 
human neutrophlls  can readily utilize exogenously-provided 
1-hexadecyl-2-1yso-GPC for the synthesis of 1-hexadecyl- 
2-acetyl-GPC (59). Finally, very recent studies have shown 
that relatively low concentrations oflyso-PC transcription- 
ally regulate growth factor gene expression in human mono- 
cytes and endothelial cells (60,  61).  Taken together, these 
data imply that lyso-phospholipids have great potential to 
affect lung injury. 
In contrast to  the  potential deleterious impact of lyso- 
phospholipids, these lyso-phospholipids may represent key 
intermediates in pathways for generating new surfactant or 
for membrane lipid remodeling. Alternatively, several stud- 
ies indicate that polyunsaturated acyl residues  of phospho- 
lipids can undergo oxidative damage and fragmentation in 
the presence of free radicals generated by activated inflam- 
matory cells  (for a review see  reference 62).  Watson and 
colleagues have further demonstrated that acetyl hydrolase 
has the capacity to cleave many of these oxidatively frag- 
mented  phospholipids  to  form  lyso-phospholipids  (63). 
Therefore, lyso-phospholipids observed in our studies may 
represent the product of clearance of oxidatively damaged 
phospholipids by lipases such as acetyl hydrolase. 
With regard to the question of mechanism of formation, 
again it is difficult to unequivocally predict how lyso-phos- 
pholipids are formed during antigen challenge. Acute respi- 
ratory failure associated  with disorders  such as pancreatitis 
correlates  with  serum  levels  of PLA  2 (46). We  recently 
demonstrated that nasal lavage  of allergic  subjects  contains 
PLA2 activity and lyso-phospholipids and that both are en- 
hanced markedly following nasal challenge with antigen or 
histamine (43, 57). The nasal lavage PLA2 was purified and 
found to be similar to a recombinant form of human PLA2 
identified in synovial fluids from patients with arthritis (43). 
The current study shows that a secretory PLA  2 is present in 
BALF of normal and allergic subjects  and that this activity 
was increased significantly in allergic  subjects  after antigen 
challenge. This activity was also blocked by a neutralizing 
antibody directed against  synovial fluid PLA2 and dithio- 
threitol, consistent with characteristics  of a low molecular 
mass secretory PLA2. Although there is no direct evidence 
that secretory PLA2 contributes to lyso-phospholipid gen- 
eration in human airways, group I PLA2 has been shown to 
induce lyso-phospholipid formation in hamster lung prepa- 
rations  (33). Other  studies  have  demonstrated  that  mast 
cells contain group II PLA2 and release this enzyme during 
the antigen-induced cross-linking of IgE (39,  40).  There- 
fore,  it  may be  that  human  mast  cells  release  secretory 
PLA2s  which,  in  turn,  hydrolyze lung  phospholipids  to 
form lyso-phospholipids. 
The  lung source  of the  phospholipid substrate  for the 
PLA2 reaction is unknown. In the hamster lung, surfactant 
phospholipids were suggested to be the preferred substrate for 
secretory PLA  2. As mentioned above, PLA  2 has been shown 
to  destroy the activity of isolated lung surfactant and this 
loss of activity has been postulated to be due to the forma- 
tion oflyso-phospholipids. Interestingly, the ratio of 1-myris- 
toyl-2-1yso-GPC to  1-palmitoyl-2-1yso-GPC observed  in 
these studies correlates well with the 1-myristoyl-2-palmi- 
toyl-GPC to 1-palmitoyl-2-palmitoyl-GPC ratio in human 
lung surfactant. However, the presence  of relatively large 
amounts 1-hexadecyl-2qyso-GPC suggest that cellular phos- 
pholipids in the lung may also serve  as a substrate  for se- 
creted PLA2. Group I and Group II PLA2 can interact with 
various cells through specific receptors on their plasma mem- 
branes  (64,  65)  and  this  may account for high levels  of 
other lysophospholipids in BALF of antigen-challenge in- 
dividuals. 
As mentioned above,  it is  also possible  that lyso-phos- 
pholipids are  formed by the hydrolysis of 2-acetylated or 
oxidatively damaged phospholipids released  into the lung. 
This hypothesis is supported by the fact that acetyl hydro- 
lase levels  in BALF increase in a time-dependent manner 
following antigen challenge.  However, two lines of reason- 
ing argue against acetyl hydrolase generating the bulk of the 
observed lyso-phospholipids. First,  the  ratios  of 1-myris- 
toyl-,  1-palmitoyl- and  1-hexadecyl-2-1yso-GPC, do  not 
fit the pattern of 2-acetylated phospholipids thought to be 
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ample,  previous studies  suggest little  1-myristoyl-2-acetyl- 
GPC and more  l-hexadecyl-2-acetyl-GPC are synthesized 
by mast cells within  the  lung  (66).  Second,  high levels of 
2-acetylated phospholipids such as PAF would be required 
in airways to serve as a substrate  for acetyl hydrolase.  This 
would seem unlikely since we were unable to measure lev- 
els much higher than 50 pg/ml of BALF at any time point 
after antigen challenge. However, this does not rule out the 
possibility that large quantities of oxidatively-damaged phos- 
pholipids  are  formed  during  antigen  challenge  and  lyso- 
phospholipids observed in the late phase are a result, in part, 
of acetyl  hydrolase-catalyzed  cleavage  of these  phospho- 
lipids. 
In conclusion, lyso-phosphatidylcholine levels are mark- 
edly elevated  in  BALF  obtained  20  h  after  antigen  chal- 
lenge from allergic subjects. The elevated lyso-phospholip- 
ids  are likely a  result of elevated  secretory PLA2 or acetyl 
hydrolase levels.  This  antigen-dependent  accumulation  of 
lyso-phospholipids in the lung may play an important role 
in the disrupted airways permeability,  barrier function and 
surfactant properties  characteristic  of late inflammatory re- 
sponses. 
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